Table 3.
Percentage change in CTX and P1NP levels from baseline (AECOPD) to 1- and 3-month follow-up excluding patients who had osteoporosis and those who had taken bisphosphonates, denosumab or synthetic human parathyroid within the 12 months before inclusion
| Total N = 279 | Baseline (μg/L) N = 264 |
1 month (difference from baseline (95% CI)) N = 193 |
3 months (difference from baseline (95% CI)) N = 179 |
|---|---|---|---|
|
CTX Low-dose group |
257 |
− 26% (− 36, − 14%); p = 0.0002 |
−14% (− 27, 1%); p = 0.063 |
|
CTX High-dose group |
257 |
−32% (− 40, − 22%); p < 0.0001 |
− 30% (− 40, − 19%); p < 0.0001 |
| Relative difference between treatment groupsa |
8% (−10, 31%); p = 0.40 |
23% (0, 51%); p = 0.049 |
|
|
P1NP Low-dose group |
22 |
65% (49, 83%); p < 0.0001 |
55% (38, 73%); p < 0.0001 |
|
P1NP High-dose group |
22 |
62% (48, 78%); p < 0.0001 |
60% (44, 78%); p < 0.0001 |
| Relative difference between treatment groupsa |
2% (−11, 16%); p = 0.80 |
−4% (− 17, 12%); p = 0.63 |
|
|
P1NP/CTX ratio Low dose group |
0.10 |
2.29 (1.98–2.65) p < 0.0001 |
2.20 (1.89; 2.56) p < 0.0001 |
|
P1NP/CTX ratio High dose group |
0.10 |
2.22 (1.89–2.60) p < 0.0001 |
1.80 (1.53; 2.12) p < 0.0001 |
| Relative difference between treatment groupsa |
0.97 (0.81; 1.17) p = 0.74 |
0.82 (0.67; 1.00) p = 0.052 |
athe relative difference between groups is calculated as the time–group interaction at the specific visit
Abbreviations: CTX C-terminal telopeptide of type 1 collagen, P1NP procollagen type 1 N-terminal propeptide